The Gift of the OMERACT Filter

Jasvinder Singh, MD, MPH University of Alabama at Birmingham Birmingham Veterans Affairs Medical Center Mayo Clinic College of Medicine On Behalf of the OMERACT Steering Committee

Sincere thanks to Maarten Boers, MSC, MD, PhD at VU University Medical Center Amsterdam, Netherlands for slides

Outline

- What is a core set and why do we need them?
 - Issues with Trials
- Current initiatives to develop core sets
 - Outcome Measures in Rheumatology (OMERACT)
 - Core Outcome Measures in Effectiveness Trials (COMET)
- Existing definitions, conceptual structures and their history
- OMERACT proposal for core areas of measurement

Problems with trials

- Trials are done to evaluate whether an intervention is effective and safe
- Choice of measures to reflect benefit and harm
- In most areas choices not standardized
 - heterogeneity between trials
 - potential for bias (selective outcome reporting)
 - choice of measures less relevant to users

Solution

Development of trial core sets

- Minimum set of outcomes that should be measured and reported in all clinical trials of a specific condition
- What is an outcome?
- How to decide what belongs in a core set?

"Outcome ME asures in R heumatoid A rthritis C linical Trials"

Outcome Measures in Rheumatology*

- Informal, unofficial
- Group of health professionals and patient experts interested in outcome measures and endpoints in rheumatology

Rheumatology, 1980-1990 No consensus over which measures to include in RA trials

- >25 different measures available
- 5 meetings: no single consensus
 - Confusion: purpose, focus of measurement, and selection of measures
 - Increasing recognition of the importance of sensitivity to change
 - Transatlantic divide

OMERACT 1 Maastricht, 1992

Core set for RA trials
 Minimum relevant improvement patients/trials

Composite measures/ improvement criteria

WHO/ILAR core set RA clinical trials

- global assessments patient & assessor
- pain
- painful joint count
- swollen joint count
- physical disability
- acute phase protein
- In studies ≥ 1 year: X-rays hands & feet

OMERACT 11 (Pinehurst, 2012)

preconference symposium

CAT/IRT

mini-module

- Psoriatic Arthritis
 workshops
- Worker Productivity
- Acute Gout
- Ultrasound responsiveness RA
- Vasculitis
- OMERACT Filter 2.0
 - Truth: Areas/Domains
 - Truth: Instruments
 - Discrimination & Feasibility
 - Putting it all together
 - Patient Reported Outcomes
 - Imaging & Biomarkers

extra activities

- Fellow training
 extended interest group
- Flares in RA special interest groups
- Myositis
- MRI-Juvenile Infl. Arthritis
- PROMIS
- Hand Osteoarthritis
- Equity
- Polymyalgia Rheumatica
- MRI-inflammatory arthritis
- Item Response Theory
- Hip Osteoarthritis
- Connective Tissue Disease/ Interst. Lung disease

9

Bottom line Achieving consensus over measures involves:

Content

- Education in methodology
- Agreeing on:
 - Purpose
 - Domain(s)
 - Applicability of specific measures
- Iteration

Bottom line Achieving consensus over measures involves:

Content

- Process
 - Data-driven
 - Iterative, stepwise
 - Inclusivity
 - Important role for dissenters
 - Harsh data softened by political considerations

OMERACT Filter to select measures

To be applicable in its intended setting, a measure must be

truthful

discriminative

feasible

OM&core Boston 13

Truth

free from bias
 criterion, construct validity
 relevant
 content, face validity

Discrimination

able to distinguish between states that are of interest:

at one time point
at different time points
reliability, reproducibility, sensitivity to change

Feasibility

timecostsinterpretability

- Filter works best to select instruments once the areas of measurement have been decided on
- Truth: "...measure what it's supposed to..." but how to decide on the supposition?

 For any core set we need to decide in what areas we need to measure core areas of measurement

Example WHO/ILAR core set rheumatoid arthritis clinical trials

- global assessments by patient & assessor
- pain
- painful joint count
- swollen joint count
- physical disability
- acute phase protein

In studies ≥ 1 year: X-rays hands & feet

RA core set & outcome

Outcome:

- "how a patient feels, functions or survives"
 - patient global
 - pain
 - physical function
- Disease activity
 - assessor global
 - swollen and tender joint counts
 - acute phase protein
- Damage: X-rays

Patient input in OMERACT started in 2002

- Core set is deficient because it does not include enough (patient-important) outcome measures
 - Fatigue
 - Sleep Quality
- ...Content validity problem!...Core area problem!
- To decide on core sets, we need to define core areas first

Core areas of measurement

Core areas of measurement

- Def.: areas that should always be addressed by measures included in a core set for trials aimed at a specific health condition
- to decide on core areas, we need:
 - a conceptual structure of health and health conditions
 - consensus on which areas in this structure are core
 - consensus on whether core areas are generic or specific to a certain health condition

Definitions

health

- health intervention
- core area: aspect of a health condition that needs to be measured to appropriately assess the effects of a health intervention.
- (sub)domain: component of core area: a concept to be measured, a further specification of an aspect of health, categorized within a core area.

Definitions

health

- health intervention
- core area: essential aspect of a health condition..
- (sub)domain: construct within a core area
- outcome: any identified result in a (sub)domain arising from exposure to a causal factor or a health intervention.
- measurement instrument: a tool to measure a quality or quantity of a variable.

Existing conceptual structures and their history

WHO 2001

International Classification of Functioning (ICF)

 universal classification of human functionality, both positive and negative



Concepts

Impact of Health Conditions Pathophysiological Manifestations











* in all areas, domains can be generic or made more specific:



specific:



* in all areas, domains can be generic or made more specific:



separately to allow assessment of benefit and harm.

* in all areas, domains can be generic or made more specific:





Core Domain Set

agreement on *what* to measure at least one Domain from each Core Area

Core Domain Set

agreement on *what* to measure at least one Domain from each Core Area



Core Outcome Measurement Set

agreement on *how* to measure at least one applicable Instrument per Domain

Developing a Core Outcome Measurement Set

Core Domain Set



Developing a Core Outcome Measurement Set





Developing a Core Outcome Measurement Set





Thank YOU! Questions, Comments...